



PRESS RELEASE

Collectis SA Combined General Shareholders' Meeting of June 27, 2014

June 30, 2014 – Paris (France) – The Combined General Shareholders' Meeting of Collectis (Alternext: ALCLS) was held on Friday, June 27, 2014 in Paris, at the Group's headquarters.

At the end of the meeting, during which more than 43,8% of voting rights were exercised, 21 of the 22 resolutions had been adopted.

21 resolutions received more than 96,5% votes in favor. Resolution No. 22, which did not have the Board of Directors' recommendation, was rejected.

In particular, Collectis' shareholders voted on:

- the approval of the parent company and consolidated financial statements for the fiscal year ended December 31, 2013;
- the renewal as directors the term of office of Ms Annick Schwebig, Mr Pierre Bastid and Mr Laurent Arthaud ;
- the approval of regulated agreements;
- the authorization of a share repurchase plan and the authorization given to the Board of Directors to retire the shares acquired through it;
- various delegations of authority and financial authorizations granted to the Board of Directors.

[The full results of the vote](http://www.collectis.com) can be examined on the company's website (www.collectis.com).

The Combined General Shareholders' Meeting provided an opportunity for André Choulika, Chairman and Chief Executive Officer, to explain the way in which the Group is positioning itself as a key player in the field of oncology and is playing a full part in the therapeutic revolution taking place in the field of adoptive immunotherapy to fight cancer with T lymphocytes bearing a CAR. In this connection, André Choulika put into perspective the various agreements reached since the beginning of the year.

About Collectis

Collectis is a biopharmaceutical company focused on oncology. The company's mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Collectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-of-the-art electroporation technology Pulse Agile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Collectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Collectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets. Collectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.collectis.com

For more information, please contact:

Collectis

Philippe Valachs

Phone: +33 (0)1 81 69 16 00

e-mail: media@collectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.